Biotech Values

[exwannabe]

>CARA vs TRVN

I have only taken a quick look at CARA.

Their pain drug had P2 results in post op almost 2 years ago, but all I have seen was stat sig vs placebo. No comparison to opiods.

Given that, combined with the fact they have not progressed to P3, I would assume they do not see a place in that space. Instead looking for a much less addictive oral. That might well be good for them, but does not really compete with TRVN in post op (which is my basis for buying TRVN).

On your comment about the heart drug, I basically agree. But one side point is that AGN did pay to extend the current study, which tends to imply decent odds of them picking up the drug this winter. Not saying that means the drugs works, but would certainly make the investment thesis better if AGN was to do such.